DALLAS, Nov. 20, 2020 /PRNewswire/ — Puration, Inc. (OTC PINK: PURA) today announced launching a campaign to build a coalition of hemp famers under one brand name in the same way that Sun-Maid Raisins brings together over 800 induvial farmers to market raisins under one brand.
The marketing campaign launched today is part of PURA’s recently launched hemp lifestyle brand initiative to engage hemp advocate consumers in an overall ecosystem designed to collectively expand the base of knowledge surrounding the economic and environmental benefits of hemp and in so doing grow the overall hemp market.
Just as Sun-Maid Raisins is a conduit for the sales of raisins from many raisin farmers, PURA plans to be a conduit for the sales of hemp from many hemp framers.
PURA has recently published a multimedia presentation on its overall hemp lifestyle brand strategy and Mr. Shibley has further elaborated on the hemp lifestyle brand strategy in a video interview conducted by CEO Roadshow.
The centerpiece of PURA’s hemp lifestyle strategy is a recently acquired 72-acre property in Farmersville, Texas where PURA plans to partner with consumer advocates and other hemp industry companies to build demonstrable hemp based products and services that expand market-wide awareness of hemp’s economic and environmental benefits.
PURA has already announced pharmaceutical and neurocritical hemp extraction partnership with PAO Group, Inc. (OTC Pink: PAOG) and co-packing partnership with Alkame Holdings, Inc. (OTC Pink: ALKM) that are key components of PURA’s overall hemp lifestyle brand initiative.
Sign up to receive the latest updates at www.purationinc.com.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.